Sfoglia per Rivista
The oral PKC-Beta inhibitor enzastaurin (LY317615) inhibits proliferation and induces apoptosis in multiple myeloma cell lines
2007 D. Verdelli, L. Nobili, K. Todoerti, L. Lombardi, S. Marmiroli, M. Civallero, M. Cosenza, J. Bertacchini, G. Lambertenghi Deliliers, A. Neri, S. Sacchi
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs
2019 V. Montefusco, F. Gay, S. Spada, L. De Paoli, F. Di Raimondo, R. Ribolla, C. Musolino, F. Patriarca, P. Musto, P. Galieni, S. Ballanti, C. Nozzoli, N. Cascavilla, D. Ben-Yehuda, A. Nagler, R. Hajek, M. Offidani, A.M. Liberati, P. Sonneveld, M. Cavo, P. Corradini, M. Boccadoro
Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection : a study on behalf of the Fondazione italiana linfomi
2014 M. Merli, C. Visco, M. Spina, S. Luminari, V. Ferretti, M. Gotti, S. Rattotti, V. Fiaccadori, C. Rusconi, C. Targhetta, C. Stelitano, A. Levis, A. Ambrosetti, D. Rossi, L. Rigacci, A. D'Arco, P. Musto, A. Chiappella, L. Baldini, M. Bonfichi, L. Arcaini
Oxidative status in essential thrombocythemia
2014 A. Iurlo, R. De Giuseppe, D. Cattaneo, C. Bucelli, N. Orofino, P. Bianchi, C. De Vita, D. Consonni, U. Gianelli, F. Bamonti, A. Cortelezzi
Oxidative stress modulates heme synthesis and induces peroxiredoxin-2 as a novel cytoprotective response in ß-thalassemic erythropoiesis
2011 L. De Franceschi, M. Bertoldi, L. De Falco, S. Santos Franco, L. Ronzoni, F. Turrini, A. Colancecco, C. Camaschella, M. D. Cappellini, A. Iolascon
p66Shc deficiency in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape
2019 L. Patrussi, N. Capitani, C. Ulivieri, N. Manganaro, M. Granai, F. Cattaneo, A. Kabanova, L. Mundo, S. Gobessi, F. Frezzato, A. Visentin, F. Finetti, P.G. Pelicci, M.M. D'Elios, L. Trentin, G. Semenzato, L. Leoncini, D.G. Efremov, C.T. Baldari
PAR-1 and PAR-2 activation mediates tissue factor induction in endothelial cells through a redox-sensitive signaling pathway
2006 C. Banfi, M. Brioschi, S.S. Barbieri, S. Eligini, S. Barcella, E. Tremoli, S. Colli, L. Mussoni
Paracrine up-regulation of monocyte cyclooxygenase-2 by platelets : role of TGF-beta1
2008 S. Eligini, S.S. Barbieri, I. Arenaz, M. Crisci, E. Tremoli, S. Colli
Paraproteinemic related neuropathies
2007 E. Nobile-Orazio
Parnaparin reduces the extent of damage in rat brain ischemia : a nuclear magnetic resonance imaging study
2006 P. Gelosa, M. Cimino, U. Guerrini, F. Calanni, E. Tremoli, L. Sironi, L. Mussoni
Pathogenesis and treatment of acquired idiopathic thrombotic thrombocytopenic purpura
2010 F. Peyvandi, R. Palla, L.A. Lotta
Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease)
2003 P.M. Mannucci, M. Karimi, A. Mosalaei, M.T. Canciani, F. Peyvandi
Patterns of global DNA methylation identify early stage (Binet A) CLL patients with higher risk of disease progression
2012 G. Tuana, L. Agnelli, L. Mosca, G. Cutrona, A. Rinaldi, S. Matis, M. Gentile, F. Di Raimondo, C. Musolino, N. Di Renzo, F.R. Mauro, S. Neri, F. Ilariucci, E. Pesce, F. Angrilli, G.M. Quintana, U. Consoli, G. Bertoldero, M.G. Lipari, P. Di Tonno, A. Fragasso, S. Molica, P. Musto, M.C. Cox, G. Festini, I. Vincelli, S. Sacchi, A. Cortelezzi, G. Lambertenghi Deliliers, F. Bertoni, F. Morabito, M. Ferrarini, A. Neri
A peculiar B-Cell subset, frequently IGVH hipermutated, is identified by a simplified immunophenotype-fish diagnostic algorithm
2005 L. Cro, L. Nobili, F. Berttoni, M. Goldaniga, A. Guffanti, S. Luminari, N. Zucal, G. Ciceri, D. Intini, A. Neri, L. Baldini, G. Lambertenghi Deliliers
Pegylated G-CSF after autologous hematopoietic stem cell transplantation
2007 C. Annaloro, P. Usardi, A. Della Volpe, F. Onida, C. Basilico, G. Lambertenghi Deliliers
Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma
2007 G. Gahrton, S. Iacobelli, G. Bandini, B. Björkstrand, P. Corradini, C. Crawley, U. Hegenbart, G. Morgan, N. Kröger, A. Schattenberg, S.O. Schönland, L.F. Verdonck, L. Volin, T. de Witte, D. Niederwieser, M. subcommittee of the EBMT
A Phase 2 multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy
2018 M. Trněný, G. Verhoef, M.J. Dyer, D.B. Yehuda, C. Patti, M. Canales, A. Lopez, F.T. Awan, P.G. Montgomery, A. Janikova, A.M. Barbui, K. Sulek, M.J. Terol, J. Radford, A. Guidetti, M. Di Nicola, L. Siraudin, L. Hatteville, S. Schwab, C. Oprea, A.M. Gianni
Phase I study of the heparanase inhibitor Roneparstat: an innovative approach for multiple myeloma therapy
2018 M. Galli, M. Chatterjee, M. Grasso, G. Specchia, H. Magen, H. Einsele, I. Celeghini, P. Barbieri, D. Paoletti, S. Pace, R.D. Sanderson, A. Rambaldi, A. Nagler
A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients
2015 A. Tedeschi, D. Rossi, M. Motta, G. Quaresmini, M. Rossi, M. Coscia, A. Anastasia, F. Rossini, A. Cortelezzi, G. Nador, L. Scarfo, R. Cairoli, A.M. Frustaci, D. Dalceggio, P. Picardi, L. de Paoli, E. Orlandi, A. Rambaldi, M. Massaia, G. Gaidano, M. Montillo
A phase II study on intensive all type chemotherapy with minimal residual disease (MRD) oriented postremission strategy in adult patients with lymphoblastic lymphoma (PROTOCOL NILG-ALL NO.09/00)
2008 S.C. Cortelazzo, T. Intermesoli, E. Oldani, F. Ciceri, G. Rossi, E. Pogliani, A. Gallamini, C. Romani, A. Cortelezzi, A. Rambaldi, R. Bassan
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile